‘006-035-00-8,pirimicarb (ISO); 2-(dimethylamino)-5,6-dimethylpyrimidin-4-yl dimethylcarbamate,245-430-1,23103-98-2, Carc. 2 Acute Tox. 3 Acute Tox. 3 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 , H351 H331 H301 H317 H400 H410 , GHS08 GHS06 GHS09 Dgr , H351 H331 H301 H317 H410 ,, M = 10 M = 100’ ,, ‘029-002-00-X, dicopper oxide; copper (I) oxide ,215-270-7,1317-39-1, Acute Tox. 4 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 , H332 H302 H318 H400 H410 , GHS07 GHS05 GHS09 Dgr , H332 H302 H318 H410 ,,M = 100’,, ‘602-020-00-0, 1,2-dichloropropane; propylene dichloride ,201-152-2,78-87-5, Flam. Liq. 2 Carc. 1B Acute Tox. 4* Acute Tox. 4* , H225 H350 H332 H302 , GHS02 GHS08 GHS07 Dgr , H225 H350 H332 H302’ ,,,, ‘602-033-00-1,chlorobenzene,203-628-5,108-90-7, Flam. Liq. 3 Acute Tox. 4 Skin Irrit. 2 Aquatic Chronic 2 , H226 H332 H315 H411 , GHS02 GHS07 GHS09 Wng , H226 H332 H315 H411’ ,,,, ‘603-055-00-4, propylene oxide; 1,2-epoxypropane; methyloxirane ,200-879-2,75-56-9, Flam. Liq. 1 Carc. 1B Muta. 1B Acute Tox. 3 Acute Tox. 3 Acute Tox. 4 STOT SE 3 Eye Irrit. 2 , H224 H350 H340 H331 H311 H302 H335 H319 , GHS02 GHS08 GHS06 Dgr , H224 H350 H340 H331 H311 H302 H335 H319’ ,,,, ‘604-030-00-0, bisphenol A; 4,4′-isopropylidenediphenol ,201-245-8,80-05-7, Repr. 1B STOT SE 3 Eye Dam. 1 Skin Sens. 1 , H360F H335 H318 H317 , GHS08 GHS05 GHS07 Dgr , H360F H335 H318 H317’ ,,,, ‘604-092-00-9, phenol, dodecyl-, branched; [1] phenol, 2-dodecyl-, branched; [2] phenol, 3-dodecyl-, branched; [3] phenol, 4-dodecyl-, branched; [4] phenol, (tetrapropenyl) derivatives [5] , 310-154-3 [1] [2] [3] [4] [5] , 121158-58-5 [1] [2] [3] 210555-94-5 [4] 74499-35-7 [5] , Repr. 1B Skin Corr. 1C Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 , H360F H314 H318 H400 H410 , GHS08 GHS05 GHS09 Dgr , H360F H314 H410 ,, M = 10 M = 10’ ,, ‘605-013-00-0, chloralose (INN); (R)-1,2-O-(2,2,2-trichloroethylidene)-α-D-glucofuranose; glucochloralose; anhydroglucochloral ,240-016-7,15879-93-3, Acute Tox. 4* Acute Tox. 3 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 , H332 H301 H336 H400 H410 , GHS06 GHS09 Dgr , H332 H301 H336 H410 ,, M = 10 M = 10 ,C’, ‘605-022-00-X, glutaral; glutaraldehyde; 1,5-pentanedial ,203-856-5,111-30-8, Acute Tox. 2 Acute Tox. 3 STOT SE 3 Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 2 , H330 H301 H335 H314 H334 H317 H400 H411 , GHS06 GHS05 GHS08 GHS09 Dgr , H330 H301 H335 H314 H334 H317 H410 ,EUH071, STOT SE 3; H335: 0,5 % ≤ C < 5 % M = 1’ ,, ‘606-014-00-9, chlorophacinone (ISO); 2-[(4-chlorophenyl)(phenyl)acetyl]-1H-indene-1,3(2H)-dione ,223-003-0,3691-35-8, Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 , H360D H330 H310 H300 H372 (blood) H400 H410 , GHS08 GHS06 GHS09 Dgr , H360D H330 H310 H300 H372 (blood) H410 ,, Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,1 % STOT RE 2; H373 (blood): 0,01 % ≤ C < 0,1 % M = 1 M = 1’ ,, ‘606-021-00-7,N-methyl-2-pyrrolidone; 1-methyl-2-pyrrolidone,212-828-1,872-50-4, Repr. 1B STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 , H360D*** H335 H315 H319 , GHS08 GHS07 Dgr , H360D*** H335 H315 H319 ,,STOT SE 3; H335: C ≥ 10 %’,, ‘607-056-00-0, warfarin (ISO); 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one; [1] (S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone; [2] (R)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone [3] , 201-377-6 [1] 226-907-3 [2] 226-908-9 [3] , 81-81-2 [1] 5543-57-7 [2] 5543-58-8 [3] , Repr. 1A Acute Tox. 1 Acute Tox. 1 Acute Tox. 2 STOT RE 1 Aquatic Chronic 2 , H360D H330 H310 H300 H372 (blood) H411 , GHS08 GHS06 GHS09 Dgr , H360D H330 H310 H300 H372 (blood) H411 ,, Repr. 1A; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,5 % STOT RE 2; H373 (blood): 0,05 % ≤ C < 0,5 %’ ,, ‘607-059-00-7,coumatetralyl (ISO); 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)coumarin,227-424-0,5836-29-3, Repr. 1B Acute Tox. 2 Acute Tox. 3 Acute Tox. 2 STOT RE 1 Aquatic Chronic 1 , H360D H330 H311 H300 H372 (blood) H410 , GHS08 GHS06 GHS09 Dgr , H360D H330 H311 H300 H372 (blood) H410 ,, Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 1,0 % STOT RE 2; H373 (blood) 0,1 % ≤ C < 1,0 % M = 10’ ,, ‘607-157-00-X,difenacoum (ISO); 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin,259-978-4,56073-07-5, Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 , H360D H330 H310 H300 H372 (blood) H400 H410 , GHS08 GHS06 GHS09 Dgr , H360D H330 H310 H300 H372 (blood) H410 ,, Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood): 0,002 % ≤ C < 0,02 % M = 10 M = 10’ ,, ‘607-172-00-1, brodifacoum (ISO); 4-hydroxy-3-(3-(4′-bromo-4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)coumarin ,259-980-5,56073-10-0, Repr. 1A Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 , H360D H330 H310 H300 H372 (blood) H400 H410 , GHS08 GHS06 GHS09 Dgr , H360D H330 H310 H300 H372 (blood) H410 ,, Repr. 1A; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood): 0,002 % ≤ C < 0,02 % M = 10 M = 10’ ,, ‘607-375-00-5,flocoumafen (ISO); reaction mass of: cis-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin and trans-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin,421-960-0,90035-08-8, Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 , H360D H330 H310 H300 H372 (blood) H400 H410 , GHS08 GHS06 GHS09 Dgr , H360D H330 H310 H300 H372 (blood) H410 ,, Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,05 % STOT RE 2; H373 (blood): 0,005 % ≤ C < 0,05 % M = 10 M = 10’ ,, ‘607-623-00-2,diisobutyl phthalate,201-553-2,84-69-5,Repr. 1B,H360Df, GHS08 Dgr ,H360Df’,,,, ‘613-166-00-X, flumioxazin (ISO); 2-[7-fluoro-3-oxo-4-(prop-2-yn-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione ,—,103361-09-7, Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 , H360D H400 H410 , GHS08 GHS09 Dgr , H360D H410 ,, M = 1 000 M = 1 000’ ,, ‘613-121-00-4,chlorsulfuron (ISO); 2-chloro-N-[[(4-methoxy-6-methyl-1,3,5-triazin-2- yl)amino]carbonyl]benzenesulphonamide,265-268-5,64902-72-3, Aquatic Acute 1 Aquatic Chronic 1 , H400 H410 , GHS09 Wng ,H410,, M = 1 000 M = 100’ ,, ‘616-011-00-4,N,N-dimethylacetamide,204-826-4,127-19-5, Repr. 1B Acute Tox. 4* Acute Tox. 4* , H360D*** H332 H312 , GHS08 GHS07 Dgr , H360D*** H332 H312’ ,,,, ‘616-037-00-6,acetochlor (ISO); 2-chloro-N-(ethoxymethyl)-N-(2-ethyl-6-methylphenyl)acetamide,251-899-3,34256-82-1, Carc. 2 Repr. 2 Acute Tox. 4 STOT SE 3 STOT RE 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 , H351 H361f H332 H335 H373 (kidney) H315 H317 H400 H410 , GHS08 GHS07 GHS09 Wng , H351 H361f H332 H335 H373 (kidney) H315 H317 H410 ,, M = 1 000 M = 100’ ,, ‘616-207-00-X, polyhexamethylene biguanide hydrochloride; PHMB ,—, 32289-58-0 27083-27-8 , Carc. 2 Acute Tox. 2 Acute Tox. 4 STOT RE 1 Eye Dam. 1 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 , H351 H330 H302 H372 (respiratory tract) (inhalation) H318 H317 H400 H410 , GHS08 GHS06 GHS05 GHS09 Dgr , H351 H330 H302 H372 (respiratory tract) (inhalation) H318 H317 H410 ,, M = 10 M = 10’ ,, ‘005-020-00-3, disodium octaborate anhydrous; [1] disodium octaborate tetrahydrate [2] , 234-541-0 [1] 234-541-0 [2] , 12008-41-2 [1] 12280-03-4 [2] ,Repr. 1B,H360FD, GHS08 Dgr ,H360FD’,,,, ‘014-046-00-4,e-glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following representative composition (% given by weight): SiO 2  50,0-56,0 %, Al 2 O 3  13,0-16,0 %, B 2 O 3  5,8-10,0 %, Na 2 O < 0,6 %, K 2 O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe 2 O 3 < 0,5 %, F 2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).],—,—,Carc. 1B,H350i, GHS08 Dgr ,H350i,,,A’, ‘014-047-00-X,glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following composition (% given by weight): SiO 2  55,0-60,0 %, Al 2 O 3  4,0-7,0 %, B 2 O 3  8,0-11,0 %, ZrO 2  0,0-4,0 %, Na 2 O 9,5-13,5 %, K 2 O 0,0-4,0 %, CaO 1,0-5,0 %, MgO 0,0-2,0 %, Fe 2 O 3 < 0,2 %, ZnO 2,0-5,0 %, BaO 3,0-6,0 %, F 2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).],—,—,Carc. 2,H351 (inhalation), GHS08 Wng ,H351 (inhalation),,,A’, ‘029-015-00-0,copper thiocyanate,214-183-1,1111-67-7,Aquatic Acute 1 Aquatic Chronic 1, H400 H410 , GHS09 Wng ,H410,EUH032,M = 10’,, ‘029-016-00-6,copper(II) oxide,215-269-1,1317-38-0, Aquatic Acute 1 Aquatic Chronic 1 , H400 H410 , GHS09 Wng ,H410,,M = 100’,, ‘029-017-00-1,dicopper chloride trihydroxide,215-572-9,1332-65-6, Acute Tox. 4 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 , H332 H301 H400 H410 , GHS06 GHS09 Dgr , H332 H301 H410 ,,M = 10’,, ‘029-018-00-7, tetracopper hexahydroxide sulphate; [1] tetracopper hexahydroxide sulphate hydrate [2] , 215-582-3 [1] 215-582-3 [2] , 1333-22-8 [1] 12527-76-3 [2] , Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 , H302 H400 H410 , GHS07 GHS09 Wng , H302 H410 ,,M = 10’,, ‘029-019-01-X,copper flakes (coated with aliphatic acid),—,—, Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 , H331 H302 H319 H400 H410 , GHS06 GHS09 Dgr , H331 H302 H319 H410 ,,M = 10’,, ‘029-020-00-8,copper(II) carbonate--copper(II) hydroxide (1:1),235-113-6,12069-69-1, Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 , H332 H302 H319 H400 H410 , GHS07 GHS09 Wng , H332 H302 H319 H410 ,,M = 10’,, ‘029-021-00-3, copper dihydroxide; copper(II) hydroxide ,243-815-9,20427-59-2, Acute Tox. 2 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 , H330 H302 H318 H400 H410 , GHS06 GHS05 GHS09 Dgr , H330 H302 H318 H410 ,,M = 10’,, ‘029-022-00-9, bordeaux mixture; reaction products of copper sulphate with calcium dihydroxide ,—,8011-63-0, Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 , H332 H318 H400 H410 , GHS07 GHS05 GHS09 Dgr , H332 H318 H410 ,,M = 10’,, ‘029-023-00-4,copper sulphate pentahydrate,231-847-6,7758-99-8, Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 , H302 H318 H400 H410 , GHS07 GHS05 GHS09 Dgr , H302 H318 H410 ,,M = 10’,, ‘082-013-00-1, lead powder; [particle diameter < 1 mm] ,231-100-4,7439-92-1, Repr. 1A Lact. , H360FD H362 , GHS08 Dgr , H360FD H362 ,,Repr. 1A; H360D: C ≥ 0,03 %’,, ‘082-014-00-7, lead massive: [particle diameter ≥ 1 mm] ,231-100-4,7439-92-1, Repr. 1A Lact. , H360FD H362 , GHS08 Dgr , H360FD H362’ ,,,, ‘605-040-00-8, hydroxyisohexyl 3-cyclohexene carboxaldehyde (INCI); reaction mass of 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde and 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [1] 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [2] 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde [3] , - [1] 250-863-4 [2] 257-187-9 [3] , 130066-44-3 [1] 31906-04-4 [2] 51414-25-6 [3] ,Skin Sens. 1A,H317, GHS07 Wng ,H317’,,,, ‘607-716-00-8,bromadiolone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2 H -chromen-2-one,249-205-9,28772-56-7, Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 , H360D H330 H310 H300 H372 (blood) H400 H410 , GHS08 GHS06 GHS09 Dgr , H360D H330 H310 H300 H372 (blood) H410 ,, Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,005 % STOT RE 2; H373 (blood): 0,0005 % ≤ C < 0,005 % M = 1 M = 1’ ,, ‘607-717-00-3, difethialone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-hydroxy-2 H -1-benzothiopyran-2-one ,—,104653-34-1, Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 , H360D H330 H310 H300 H372 (blood) H400 H410 , GHS08 GHS06 GHS09 Dgr , H360D H330 H310 H300 H372 (blood) H410 ,EUH070, Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood): 0,002 % ≤ C < 0,02 % M = 100 M = 100’ ,, ‘607-718-00-9,perfluorononan-1-oic acid [1] and its sodium [2] and ammonium [3] salts, 206-801-3 [1] [2] [3] , 375-95-1 [1] 21049-39-8 [2] 4149-60-4 [3] , Carc. 2 Repr. 1B Lact. Acute Tox. 4 Acute Tox. 4 STOT RE 1 Eye Dam. 1 , H351 H360Df H362 H332 H302 H372 (liver, thymus, spleen) H318 , GSH08 GSH07 GHS05 Dgr , H351 H360Df H362 H332 H302 H372 (liver, thymus, spleen) H318’ ,,,, ‘607-719-00-4,dicyclohexyl phthalate,201-545-9,84-61-7, Repr. 1B Skin Sens. 1 , H360D H317 , GHS08 GHS07 Dgr , H360D H317’ ,,,, ‘608-067-00-3,3,7-dimethylocta-2,6-dienenitrile,225-918-0,5146-66-7,Muta. 1B,H340, GHS08 Dgr ,H340’,,,, ‘612-288-00-0, bupirimate (ISO); 5-butyl-2-ethylamino-6-methylpyrimidin-4-yl dimethylsulphamate ,255-391-2,41483-43-6, Carc. 2 Skin Sens. 1B Aquatic Chronic 1 , H351 H317 H410 , GHS08 GHS07 GHS09 Wng , H351 H317 H410 ,,M = 1’,, ‘612-289-00-6, triflumizole (ISO); (1 E )- N -[4-chloro-2-(trifluoromethyl)phenyl]-1-(1 H -imidazol-1-yl)-2-propoxyethanimine ,—,68694-11-1, Repr. 1B Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 , H360D H302 H373 (liver) H317 H400 H410 , GHS08 GHS07 GHS09 Dgr , H360D H302 H373 (liver) H317 H410 ,, M = 1 M = 1’ ,, ‘616-218-00-X,benzovindiflupyr (ISO); N -[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1 H -pyrazole-4-carboxamide,—,1072957-71-1, Acute Tox. 3 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 , H331 H301 H400 H410 , GHS06 GHS09 Dgr , H331 H301 H410 ,, M = 100 M = 100’ ,, ‘616-219-00-5,fluopyram (ISO); N -{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(trifluoromethyl)benzamide,—,658066-35-4,Aquatic Chronic 2,H411,GHS09,H411’,,,, ‘616-220-00-0,pencycuron (ISO); 1-[(4-chlorophenyl)methyl]-1-cyclopentyl-3-phenylurea,266-096-3,66063-05-6, Aquatic Acute 1 Aquatic Chronic 1 , H400 H410 , GHS09 Wng ,H410,, M = 1 M = 1’ ,, ‘617-023-00-2, tert -butyl hydroperoxide,200-915-7,75-91-2,Muta. 2,H341, GHS08 Wng ,H341’,,,,